Cutaneous melanoma is melanoma that starts in the skin, arising from melanocytes. It is relatively uncommon among skin cancers but is more aggressive and accounts for most skin-cancer deaths. Early detection is important because prognosis is strongly stage-dependent.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Phase 2 SWOG S1512 trial shows neoadjuvant pembrolizumab achieved 71% pathologic complete response in resectable desmoplastic melanoma with 3-year survival rates of 74% for relapse-free and 87% for overall survival.
Immatics received FDA orphan drug designation for its melanoma therapy targeting Stage II and higher cutaneous melanoma in HLA-A 02:01-positive patients, marking a regulatory milestone that brings potential market exclusivity benefits.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600476 |
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07519655 |
Phase 1 Study of PF-08046033 in Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07376317 |
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07251335 |
Melanoma of the Skin and Exposure to Solar Ultraviolet Radiation at Work in Modena Territory: a Case-control Study to Promote an Active Search and Prevention of Occupational Diseases Based on Recent INAIL Criteria |
RECRUITING | |
| NCT07148245 |
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma |
RECRUITING | |
| NCT07068074 |
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients |
NOT_YET_RECRUITING | PHASE3 |
| NCT06999980 |
Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) |
RECRUITING | PHASE2 |
| NCT06984328 |
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06967961 |
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers |
RECRUITING | NA |
| NCT06946225 |
ACTengine® IMA203 Combined With mRNA-4203 |
RECRUITING | PHASE1 |
